171 related articles for article (PubMed ID: 34961753)
1. Ultra-Short Course of Neo-Adjuvant Denosumab for Nerve-Sparing Surgery for Giant Cell Tumor of Bone in Sacrum.
Liang H; Liu X; Yang Y; Guo W; Yang R; Tang X; Yan T; Li Y; Tang S; Li D; Qu H; Dong S; Ji T; Du Z; Zang J
Spine (Phila Pa 1976); 2022 May; 47(9):691-701. PubMed ID: 34961753
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of short-course neoadjuvant denosumab for en bloc spondylectomy in spinal giant cell tumor of bone: a preliminary report.
Tang Q; Lu J; Zhu X; Song G; Wu H; Xu H; Wang A; Wang J
Eur Spine J; 2023 Dec; 32(12):4297-4305. PubMed ID: 37318598
[TBL] [Abstract][Full Text] [Related]
3. Short-term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone.
Zhang RZ; Ma TX; Qi DW; Zhao M; Hu T; Zhang GC
Orthop Surg; 2019 Dec; 11(6):1101-1108. PubMed ID: 31762217
[TBL] [Abstract][Full Text] [Related]
4. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
Hindiskere S; Errani C; Doddarangappa S; Ramaswamy V; Rai M; Chinder PS
Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
[TBL] [Abstract][Full Text] [Related]
5. Retrospective cohort study of 68 sacral giant cell tumours treated with nerve-sparing surgery and evaluation on therapeutic benefits of denosumab therapy.
Lim CY; Liu X; He F; Liang H; Yang Y; Ji T; Yang R; Guo W
Bone Joint J; 2020 Feb; 102-B(2):177-185. PubMed ID: 32009426
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Denosumab With Curettage and Cryotherapy in Giant Cell Tumor of Bone: Is There an Increased Risk of Local Recurrence?
Scoccianti G; Totti F; Scorianz M; Baldi G; Roselli G; Beltrami G; Franchi A; Capanna R; Campanacci DA
Clin Orthop Relat Res; 2018 Sep; 476(9):1783-1790. PubMed ID: 30778015
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
Chinder PS; Hindiskere S; Doddarangappa S; Pal U
Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
[TBL] [Abstract][Full Text] [Related]
8. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
[TBL] [Abstract][Full Text] [Related]
9. Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum.
Bukata SV; Blay JY; Rutkowski P; Skubitz K; Henshaw R; Seeger L; Dai T; Jandial D; Chawla S
Spine (Phila Pa 1976); 2021 Mar; 46(5):277-284. PubMed ID: 33038190
[TBL] [Abstract][Full Text] [Related]
10. The role of Denosumab in joint preservation for patients with giant cell tumour of bone.
Perrin DL; Visgauss JD; Wilson DA; Griffin AM; Abdul Razak AR; Ferguson PC; Wunder JS
Bone Joint J; 2021 Jan; 103-B(1):184-191. PubMed ID: 33380180
[TBL] [Abstract][Full Text] [Related]
11. Denosumab in giant cell tumour of bone in the pelvis and sacrum: Long-term therapy or bone resection?
Sambri A; Medellin MR; Errani C; Campanacci L; Fujiwara T; Donati D; Parry M; Grimer R
J Orthop Sci; 2020 May; 25(3):513-519. PubMed ID: 31155442
[TBL] [Abstract][Full Text] [Related]
12. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
Duan DK; Zhang GC; Sun BJ; Ma TX; Zhao M
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone.
Puri A; Gulia A; Hegde P; Verma V; Rekhi B
Bone Joint J; 2019 Feb; 101-B(2):170-177. PubMed ID: 30700112
[TBL] [Abstract][Full Text] [Related]
14. Intralesional nerve-sparing surgery versus non-surgical treatment for giant cell tumor of the sacrum.
Tsukamoto S; Ali N; Mavrogenis AF; Honoki K; Tanaka Y; Spinnato P; Donati DM; Errani C
BMC Musculoskelet Disord; 2021 Dec; 22(1):1023. PubMed ID: 34872538
[TBL] [Abstract][Full Text] [Related]
15. Effect of denosumab in treatment of unresectable spine and sacrum giant cell tumor of bone.
Arefpour A; Shafieesabet M; Chehrassan M; Ahmadzadehnanva A; Ghandhari H
Musculoskelet Surg; 2024 Mar; 108(1):93-98. PubMed ID: 37940782
[TBL] [Abstract][Full Text] [Related]
16. Clinical, radiological and pathological outcomes following treatment of primary giant cell tumour of bone with Denosumab.
Murphy B; Vodanovich D; Spelman T; Gullifer J; Slavin J; Powell G; Pang G; Choong P
ANZ J Surg; 2020 Dec; 90(12):2553-2558. PubMed ID: 32767541
[TBL] [Abstract][Full Text] [Related]
17. Denosumab May Increase the Risk of Local Recurrence in Patients with Giant-Cell Tumor of Bone Treated with Curettage.
Errani C; Tsukamoto S; Leone G; Righi A; Akahane M; Tanaka Y; Donati DM
J Bone Joint Surg Am; 2018 Mar; 100(6):496-504. PubMed ID: 29557866
[TBL] [Abstract][Full Text] [Related]
18. Current concepts in the treatment of giant cell tumour of bone.
van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
[TBL] [Abstract][Full Text] [Related]
19. Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.
Rutkowski P; Ferrari S; Grimer RJ; Stalley PD; Dijkstra SP; Pienkowski A; Vaz G; Wunder JS; Seeger LL; Feng A; Roberts ZJ; Bach BA
Ann Surg Oncol; 2015 Sep; 22(9):2860-8. PubMed ID: 26033180
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Denosumab and Zoledronic acid as neoadjuvant therapy in patients with giant cell tumor of bone.
Kanwat H; Banjara R; Kumar VS; Majeed A; Gamnagatti S; Khan SA
J Orthop Surg (Hong Kong); 2021; 29(2):23094990211007565. PubMed ID: 34231432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
